- Home
- BNRG vs TOVX Comparison
BNRG vs TOVX Comparison
Compare BNRG & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- TOVX
- Stock Information
- Founded
- BNRG 2012
- TOVX 2001
- Country
- BNRG Israel
- TOVX United States
- Employees
- BNRG N/A
- TOVX N/A
- Industry
- BNRG
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BNRG
- TOVX Health Care
- Exchange
- BNRG Nasdaq
- TOVX Nasdaq
- Market Cap
- BNRG 5.2M
- TOVX 4.5M
- IPO Year
- BNRG 2022
- TOVX 2006
- Fundamental
- Price
- BNRG $2.17
- TOVX $0.41
- Analyst Decision
- BNRG
- TOVX Hold
- Analyst Count
- BNRG 0
- TOVX 1
- Target Price
- BNRG N/A
- TOVX N/A
- AVG Volume (30 Days)
- BNRG 57.8K
- TOVX 359.6K
- Earning Date
- BNRG 08-13-2025
- TOVX 11-11-2025
- Dividend Yield
- BNRG N/A
- TOVX N/A
- EPS Growth
- BNRG N/A
- TOVX N/A
- EPS
- BNRG N/A
- TOVX N/A
- Revenue
- BNRG N/A
- TOVX N/A
- Revenue This Year
- BNRG N/A
- TOVX N/A
- Revenue Next Year
- BNRG N/A
- TOVX N/A
- P/E Ratio
- BNRG N/A
- TOVX N/A
- Revenue Growth
- BNRG N/A
- TOVX N/A
- 52 Week Low
- BNRG $1.64
- TOVX $0.37
- 52 Week High
- BNRG $15.30
- TOVX $4.20
- Technical
- Relative Strength Index (RSI)
- BNRG 52.30
- TOVX 48.50
- Support Level
- BNRG $2.10
- TOVX $0.38
- Resistance Level
- BNRG $2.30
- TOVX $0.44
- Average True Range (ATR)
- BNRG 0.14
- TOVX 0.02
- MACD
- BNRG 0.00
- TOVX 0.00
- Stochastic Oscillator
- BNRG 47.56
- TOVX 51.29
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.